Radiotherapy & Oncology
Volume 95, Issue 1 , Pages 23-31, April 2010

Trials and tribulations in charged particle radiotherapy

  • Michael Goitein

      Affiliations

    • Corresponding Author InformationAddress: Ankerstrasse 1, CH-5210 Windisch, AG, Switzerland.

Harvard Medical School, Boston, USA

Received 17 March 2009; received in revised form 2 June 2009; accepted 8 June 2009. published online 08 July 2009.

Abstract 

A number of aspects of radiotherapy using protons and ions such as carbon and neon are discussed, focusing less on the oft-enumerated advantages or potential advantages of these particles as on those aspects which are, or may be, problematic. First, for protons and so-called heavy ions separately, the potential advantages and disadvantages of the particles, on physical and radiobiological grounds, are reviewed and some outstanding problems, both technical and scientific, are enumerated. Then, mention is made of the danger that financial pressures can lead to suboptimal medical care of patients. Finally, the issue of clinical trials, and especially randomized clinical trials, is addressed. On the one hand, very few randomized trials have been reported. On the other hand, there is a widespread desire to see trials of charged particle therapy undertaken. The ethical considerations are briefly reviewed and it is concluded that they pose strong limitations on the types of trials which can be undertaken. Nevertheless, some clinical trials would certainly be appropriate and desirable and a number are suggested, under the categories of retrospective non-randomized clinical trials, prospective non-randomized clinical trials, and prospective-randomized clinical trials.

Keywords: Charged particles, Proton therapy, Heavy-ion therapy, Carbon-ion therapy, Clinical trials, Randomized clinical trials

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Delivered as the 29th Elis Berven lecture at the 2009 annual meeting of the Swedish Society of Oncology.

PII: S0167-8140(09)00316-8

doi:10.1016/j.radonc.2009.06.012

Radiotherapy & Oncology
Volume 95, Issue 1 , Pages 23-31, April 2010